Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Geneos Therapeutics has raised $5.0M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Geneos Therapeutics's investors include Sante Ventures, 3B Future Health Fund, Korea Investment Partners, Inovio Pharmaceuticals, Shanghai Healthcare Capital.
Geneos Therapeutics is headquartered in Plymouth Meeting, United States.
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Geneos Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Geneos Therapeutics — Funding & Investors." VCBacked, September 27, 2023, https://www.vcbacked.co/company/geneos-therapeutics. Accessed September 14, 2026.
VCBacked. (2023). Geneos Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/geneos-therapeutics
{{cite web |title=Geneos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/geneos-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated